Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 51 Show results per page	View Search Criteria \| Help With Results


1.		Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Active				18 and over				Other				2006-00055-18 NCT00415103

Last Modified: 6/9/2008 First Published: 7/1/1999


2.		Phase II/III Study of Standard and Novel Conditioning Therapy and Allogeneic Blood or Marrow Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 to 65				Other				RPCI-RP-9815 NCI-V99-1527, NCT00003816, RP 98-15

Last Modified: 6/9/2008 First Published: 9/26/2007


3.		Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 and over				NCI				RPCI-I-72806 I 72806, NCT00536601

Last Modified: 3/14/2008 First Published: 3/1/2001


4.		Phase III Randomized Study of Sequential Chemotherapy With or Without Rituximab Followed By Ablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Relapsed, CD20 Positive, Aggressive B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 65				Other				CKTO-2000-06 HOVON-44, HOVON-44/CKVO-2000-06, EU-20042, ISRCTN95614846, NCT00012051

Last Modified: 7/1/2008 First Published: 3/24/2004


5.		Phase III Randomized Study of Rituximab, Ifosfamide, Carboplatin, and Etoposide Versus Rituximab, Dexamethasone, Cytarabine, and Cisplatin as Induction Therapy Followed By High-Dose Consolidation Chemotherapy and Autologous Stem Cell Transplantation With Versus Without Rituximab as Maintenance Therapy in Patients With Relapsed or Refractory CD20-Positive Diffuse Large B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 65				NCI				MSKCC-03139 CORAL-50-03B, NCT00137995


6.		Efficacy of Rituximab - Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus R-CHOP/R-DHAP in Patients With Untreated Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 65				Other				MCL2004-2 NCT00209222


7.		Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 80				NHLBI				384 BMT CTN 0401, U01 HL069294-05, NCT00329030

Last Modified: 6/19/2008 First Published: 2/5/2007


8.		Phase III Randomized Study of Combination Chemotherapy in Pediatric Patients With Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Diagnostic, Treatment				Active				Under 18				Other				EURONET-PHL-C1 EU-20703, EUDRACT-2006-000995-33, NCT00433459, CCLG-HD-2007-10


9.		GEM05 for Patients With Multiple Myeloma Under 65 Years

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				65 and under				Other				2005-001110-41 NCT00461747


10.		Zevalin and BEAM High-Dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin’s Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 to 65				Other				Sor451107ctil NCT00463463

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute